Given that approximately 10–15% of endometrioid tumors are ER-negative and that grade 3 tumors are biologically distinct—often associated with TP53 mutations and worse outcomes—this grouping may have introduced heterogeneity. The gene discussed is TP53; the disease is endometrioid tumor.